Ivabradine Synthon (Ivabradine Hydrochloride)

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the heart’s natural pacemaker. By inhibiting this inward sodium/potassium current, the drug slows the spontaneous depolarisation of pacemaker cells, leading to a reduction in heart rate without affecting contractility or blood pressure.

The dosage of Ivabradine Synthon is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate response, and tolerability. The prescriber will select the appropriate strength and dosing schedule according to current guidelines and individual patient factors.

Safety data for ivabradine in pregnancy and lactation are limited, and the product does not have an established pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus, and breastfeeding mothers should consult their healthcare provider before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but they act via different mechanisms. Beta‑blockers reduce heart rate by blocking adrenergic receptors and also decrease contractility, whereas ivabradine selectively inhibits the If current without affecting contractility. Ivabradine may be preferred when beta‑blockers are contraindicated or not tolerated.

Ivabradine Synthon should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Ivabradine Synthon is taken orally, usually with or without food, as directed by the prescribing physician. The tablets should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise instructed by a healthcare professional.

The most serious adverse events include severe bradycardia, atrial fibrillation, symptomatic hypotension, and rare visual disturbances that may lead to persistent visual loss. Patients should be monitored for these events, especially during dose initiation and when combined with other heart‑rate‑lowering agents.

Ivabradine Synthon is contraindicated in patients with severe hepatic impairment, sick sinus syndrome, second‑ or third‑degree atrioventricular block (unless a pacemaker is present), and in those taking strong CYP3A4 inhibitors such as ketoconazole. It should also be used with caution in patients with unstable angina or acute myocardial infarction.